Change Healthcare Valuation
Is CHNG * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CHNG * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CHNG * (MX$433) is trading below our estimate of fair value (MX$513.54)
Significantly Below Fair Value: CHNG * is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CHNG *?
Other financial metrics that can be useful for relative valuation.
What is CHNG *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$9.03b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.9x |
Enterprise Value/EBITDA | 19.4x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CHNG *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 7.7x | ||
2413 M3 | 5.4x | 10.0% | JP¥1.3t |
DOCS Doximity | 9.9x | 9.8% | US$4.6b |
EVH Evolent Health | 1.7x | 14.0% | US$3.4b |
SECT B Sectra | 13.9x | 13.9% | kr39.7b |
CHNG * Change Healthcare | 2.6x | 4.7% | Mex$9.0b |
Price-To-Sales vs Peers: CHNG * is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (10.9x).
Price to Earnings Ratio vs Industry
How does CHNG *'s PE Ratio compare vs other companies in the Global Healthcare Services Industry?
Price-To-Sales vs Industry: CHNG * is good value based on its Price-To-Sales Ratio (2.6x) compared to the Global Healthcare Services industry average (3.6x).
Price to Sales Ratio vs Fair Ratio
What is CHNG *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 2.6x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate CHNG *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Apr ’25 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Mar ’25 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Feb ’25 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Jan ’25 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Dec ’24 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Nov ’24 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Oct ’24 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Sep ’24 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Aug ’24 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Jul ’24 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Jun ’24 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
May ’24 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Apr ’24 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Mar ’24 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Feb ’24 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Jan ’24 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Dec ’23 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Nov ’23 | n/a | Mex$546.50 0% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Oct ’23 | Mex$433.00 | Mex$546.50 +26.2% | 3.0% | Mex$555.40 | Mex$515.37 | n/a | 9 |
Sep ’23 | Mex$433.00 | Mex$522.94 +20.8% | 8.2% | Mex$554.14 | Mex$419.35 | n/a | 8 |
Aug ’23 | Mex$433.00 | Mex$530.38 +22.5% | 8.0% | Mex$567.44 | Mex$429.41 | n/a | 8 |
Jul ’23 | Mex$433.00 | Mex$530.38 +22.5% | 8.0% | Mex$567.44 | Mex$429.41 | n/a | 8 |
Jun ’23 | Mex$433.00 | Mex$506.74 +17.0% | 8.1% | Mex$547.62 | Mex$414.41 | n/a | 7 |
May ’23 | n/a | Mex$519.26 0% | 6.3% | Mex$536.01 | Mex$432.93 | n/a | 8 |
Apr ’23 | n/a | Mex$519.26 0% | 6.3% | Mex$536.01 | Mex$432.93 | n/a | 8 |
Analyst Forecast: Target price is lower than the current share price.